effect of anti-obesity drug on cardiovascular risk factors a systematic review and meta-analysis of randomized controlled trials抗肥胖药物对心血管风险的影响因素随机对照试验的系统性回顾和荟萃分析.pdfVIP

Effect of Anti-Obesity Drug on Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials 1. 1. 1. 1. 2 3 1 Yu-Hao Zhou , Xiu-Qiang Ma , Cheng Wu , Jian Lu , Shan-Shan Zhang , Jia Guo , Shun-Quan Wu , 1 1 1 Xiao-Fei Ye , Jin-Fang Xu , Jia He * 1 Department of Health Statistics, Second Military Medical University, Shanghai, China, 2 Tumor Immunology and Gene Therapy Center, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China, 3 Department of Ultrasonography, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China Abstract Background: Anti-obesity drugs are widely used to prevent the complications of obesity, however, the effects of anti- obesity drugs on cardiovascular risk factors are unclear at the present time. We carried out a comprehensively systematic review and meta-analysis to assess the effects of anti-obesity drugs on cardiovascular risk factors. Methodology and Principal Findings: We systematically searched Medline, EmBase, the Cochrane Central Register of Controlled Trials, reference lists of articles and proceedings of major meetings for relevant literatures. We included randomized placebo-controlled trials that reported the effects of anti-obesity drugs on cardiovascular risk factors compared to placebo. Overall, orlistat produced a reduction of 2.39 kg (95%CI-3.34 to 21.45) for weight, a reduction of 0.27 mmol/L (95%CI: 20.36 to 20.17) for total cholesterol, a reduction of 0.21 mmol/L (95%CI: 20.30 to 20.12) for LDL, a reduction of 0.12 mmol/L (95%CI: 20.20 to